Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...
The Global Recombinant DNA Technology Market was valued at approximately USD $$ billion in 2022 and is expected to grow at a healthy CAGR of over $% from 2023 to 2030. Recombinant DNA Technology ...
Objectives Tendinopathy is a frequent clinical problem and represents an extraordinary health economic and socioeconomic burden with high unmet medical needs. Recent clinical evidence suggests ...